Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAK694 in seasonal allergic rhinitis
NCT00929968Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2009
- Primary completion
- Feb 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of vak694 in allergic rhinitis (AR), sponsored by Novartis. Started Jun 2009; status: completed.
02
Drugs
vak694
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT00929968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00929968.